AAV Gene Therapy Vector Purification
Adeno-associated virus vector purification — cell lysis, nuclease treatment, affinity capture, ion exchange polishing, and UF/DF formulation for GMP gene therapy manufacturing
Process Overview
AAV (adeno-associated virus) vectors are the leading platform for in vivo gene therapy, with approved products including Zolgensma (AAV9), Luxturna (AAV2), and Hemgenix (AAV5). The downstream process must separate full (genome-containing) capsids from empty capsids, host cell proteins, host cell DNA, and residual plasmid DNA while maintaining vector potency. Yields are inherently low (10–30% overall) due to the fragile nature of the 25 nm capsid and stringent purity requirements. Typical batch output: 10¹³–10¹⁵ vector genomes (vg).
Process Steps
1
Cell Disruption
Cell Lysis
HEK293 cells (adherent or suspension) are lysed to release intracellular AAV particles. Chemical lysis uses detergent (0.1% Triton X-100 or Tween 20) in hypotonic buffer with freeze–thaw cycles or microfluidization. For suspension cultures at >2 × 10⁶ cells/mL, lysis is performed directly in the bioreactor. Lysis buffer typically contains 50 mM Tris, 150 mM NaCl, 2 mM MgCl2, pH 8.0.
Yield: 80–95%
Volume: 50–200 L
2
Enzymatic Treatment
Benzonase Nuclease Digestion
Benzonase endonuclease (50–100 U/mL) is added to the lysate with MgCl2 (2 mM) and incubated at 37°C for 1–2 hours. This degrades host cell DNA and residual plasmid DNA to <200 bp fragments, reducing viscosity and preventing DNA co-purification. Critical for meeting regulatory limits of <10 ng residual host cell DNA per dose (FDA/EMA guideline). NaCl is then increased to 500 mM to dissociate AAV from cellular debris.
DNA reduction: >99%
Yield: >95%
3
Depth Filtration
Clarification
Cell debris is removed by depth filtration (Millistak+ HC or Clarisolve) followed by 0.2 μm sterile filtration. A two-stage depth filter train (2–8 μm primary, 0.2–0.6 μm secondary) handles the high cell debris load. Alternatively, tangential flow microfiltration (0.45 μm) is used for larger volumes. The clarified harvest contains AAV particles, soluble host cell proteins, DNA fragments, and media components.
Yield: 85–95%
Turbidity: <10 NTU
4
Affinity Chromatography
Affinity Capture (AAVX / AVB Sepharose)
Clarified harvest is loaded onto AAVX resin (Cytiva) or POROS CaptureSelect AAV resins (Thermo Fisher), which bind AAV capsids via a camelid-derived single-domain antibody recognizing conserved capsid epitopes. AAVX captures serotypes AAV1–9 and engineered variants. Wash with high salt (500 mM NaCl) removes >99% of host cell proteins. Elute at low pH (2.5–3.0, citrate buffer) and immediately neutralize to pH 7.0 to preserve infectivity. This step achieves >99% HCP removal in a single pass.
Yield: 60–80%
HCP removal: >99%
5
Ion Exchange Chromatography
AEX Polishing (Full/Empty Separation)
Anion exchange chromatography (CIMmultus QA monolith or POROS HQ resin) separates full capsids from empty capsids, which differ in charge density due to the packaged genome. At pH 9.0 in low-salt buffer (20 mM Bis-Tris propane), empty capsids (pI ~6.3) elute at lower NaCl (~60–80 mM) than full capsids (~100–120 mM). This is the critical quality step: full capsid enrichment from ~20–30% to >90–95% of total capsids.
Yield: 50–70%
Full capsids: >90%
6
Ultrafiltration / Diafiltration
UF/DF Formulation
Purified AAV is concentrated and buffer-exchanged using tangential flow filtration (TFF) with 100 kDa MWCO hollow fiber or cassette membranes. The product is concentrated 10–50× and diafiltered into final formulation buffer (typically PBS with 0.001% Pluronic F-68, pH 7.4). Final sterile filtration through 0.22 μm filter. Product is aliquoted, frozen at −60°C or −80°C. Final analytics: ddPCR for titer (vg/mL), ELISA for capsid concentration, AUC for full/empty ratio.
Yield: 80–95%
Titer: 10¹³–10¹⁴ vg/mL
Target Vector: AAV (Adeno-Associated Virus)
| Capsid Diameter | ~25 nm (T=1 icosahedral symmetry) |
| Molecular Weight | ~3.6 MDa (empty), ~4.7 MDa (full, with 4.7 kb ssDNA genome) |
| Isoelectric Point | ~6.3 (serotype-dependent, pH 5.9–6.9) |
| Genome Capacity | ≤4.7 kb single-stranded DNA (self-complementary: ≤2.4 kb) |
| Key Serotypes | AAV2 (retina), AAV5 (liver), AAV8 (liver), AAV9 (CNS, systemic) |
View full AAV vector page →
Cost Considerations
| Step | Key Cost Driver | Relative Cost |
|---|
| Cell Lysis | Detergent, lysis buffer volume | Low |
| Benzonase Treatment | Benzonase enzyme (expensive) | Medium |
| Clarification | Depth filters (single-use) | Low |
| Affinity Chromatography | AAVX resin (very expensive, limited cycles) | High |
| AEX Polishing | Monolith columns, buffer consumption | Medium |
| UF/DF Formulation | TFF cassettes, Pluronic excipient | Medium |
Affinity resin is the dominant cost driver. AAVX and CaptureSelect resins cost $15,000–25,000 per liter and have limited reuse cycles (50–100). For high-dose indications (e.g., Zolgensma at ~10¹⁴ vg/kg for a 70 kg adult), the downstream process can account for 50–70% of total manufacturing cost. Use
untangle.bio to model AAV process economics and explore resin reuse strategies.
Frequently Asked Questions
Why is full/empty capsid separation so challenging?
Full and empty AAV capsids are structurally identical on the outside — both are 25 nm icosahedral shells composed of VP1, VP2, and VP3 proteins. The only difference is the 1.1 MDa single-stranded DNA genome inside. This mass difference creates a subtle charge density difference exploited by AEX, and a buoyant density difference used in analytical ultracentrifugation (AUC) and CsCl gradient ultracentrifugation. No surface ligand can distinguish them.
Why is Benzonase treatment essential in AAV manufacturing?
HEK293 cells contain ~6 pg of DNA per cell. At 2 × 10⁶ cells/mL in 200 L, this yields ~2.4 g of host cell DNA. FDA/EMA guidelines require <10 ng residual DNA per dose. Benzonase degrades DNA to <200 bp fragments, reducing both quantity and oncogenic risk from large DNA fragments. Without nuclease treatment, DNA co-purifies with AAV during chromatography due to electrostatic interactions.
What are the key differences between AAV serotypes for purification?
Different AAV serotypes have varying capsid surface charges, receptor binding properties, and affinity resin binding affinities. AAV2 binds heparin sulfate (enabling heparin affinity capture), while AAV8 and AAV9 do not. AAVX resin is pan-serotype but with varying dynamic binding capacity (0.5–3 × 10¹³ vg/mL resin depending on serotype). AEX salt elution profiles differ by 10–30 mM NaCl between serotypes, requiring process-specific optimization.
Can ultracentrifugation replace chromatography for AAV purification?
CsCl density gradient ultracentrifugation (1.37–1.41 g/cm³ for full capsids vs. 1.32–1.35 for empty) was the original purification method and achieves excellent full/empty separation. However, it is limited to small scale (<10 L), requires 16–24 hour runs, uses toxic CsCl, and is difficult to validate for GMP. Chromatographic processes (affinity + AEX) are preferred for clinical and commercial manufacturing due to scalability, speed, and regulatory compliance.
Design Your AAV Purification Process
Drag-and-drop the full AAV downstream train, simulate mass balance, and estimate GMP manufacturing costs for your gene therapy program.
Open untangle.bio